Last reviewed · How we verify
Ramelteon and zolpidem
This is a fixed-dose combination of ramelteon (a melatonin receptor agonist) and zolpidem (a non-benzodiazepine hypnotic) that promotes sleep through dual mechanisms targeting different sleep-wake pathways.
This is a fixed-dose combination of ramelteon (a melatonin receptor agonist) and zolpidem (a non-benzodiazepine hypnotic) that promotes sleep through dual mechanisms targeting different sleep-wake pathways. Used for Insomnia characterized by difficulty with sleep onset and/or sleep maintenance.
At a glance
| Generic name | Ramelteon and zolpidem |
|---|---|
| Also known as | Rozerem™, TAK-375, Ambien® |
| Sponsor | Takeda |
| Drug class | Hypnotic combination agent |
| Target | Melatonin receptors (MT1/MT2) and GABA-A receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Ramelteon selectively binds to melatonin MT1 and MT2 receptors to regulate circadian rhythm and promote sleep onset, while zolpidem acts as a selective GABA-A receptor modulator to enhance sleep maintenance. The combination leverages complementary mechanisms to address both sleep initiation and consolidation in patients with insomnia.
Approved indications
- Insomnia characterized by difficulty with sleep onset and/or sleep maintenance
Common side effects
- Dizziness
- Headache
- Somnolence
- Fatigue
- Complex sleep behaviors
Key clinical trials
- Differential Effects of Zolpidem Versus Ramelteon in Burned Children (PHASE2)
- The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep (PHASE1)
- Safety of Ramelteon in Elderly Subjects (PHASE4)
- Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramelteon and zolpidem CI brief — competitive landscape report
- Ramelteon and zolpidem updates RSS · CI watch RSS
- Takeda portfolio CI